Katharina C. Kaehler, MD, on Daromun in Resectable Locally Advanced Melanoma: Trial Updates

June 10, 2026 By The ASCO Post Staff

Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant intralesional therapy in patients with resectable, locally advanced stage III melanoma (Abstract LBA9517). 

Related Content